Researchers compared the grade 12 test results of patients with childhood-onset chronic rheumatic diseases and healthy participants, and determined the factors associated with these test scores.
The American College of Rheumatology (ACR) developed and validated new Juvenile Arthritis Disease Activity Score 10 (JADAS10) and clinical JADAS10 cutoffs to distinguish between the disease activity states in children with oligoarthritis and polyarthritis.
Findings showed that treatment with secukinumab resulted in a 72% reduction in the risk of flare at week 104 compared with placebo.
Presence of two or more of these criteria has a sensitivity and specificity of more than 70 percent, the authors say
Researchers reported on the effect of the CARRA Consensus Treatment Plans on outcomes of polyarticular juvenile idiopathic arthritis at 24 months.
The panel reviewed safety and efficacy data from a phase 2/3 study that included 2268 participants who received a 2-dose regimen of 10mcg administered 21 days apart.
Researchers studied the association between schizophrenia genetic susceptibility loci and neuropsychiatric features in childhood-onset systemic lupus erythematosus.
Researchers assessed baseline index performances and identified sources of pediatric lupus care index variations.
Using PROMIS measures, the researchers evaluated the prevalence of symptoms of depression and anxiety among children with juvenile idiopathic arthritis.
Children with a genetic autoinflammatory disorder experienced meibomian gland loss, but little conjunctival cell change.